2月28日 - ** 药物开发商PRAXIS Precision Medicines PRAX.O股价盘前下跌39.2%至39.51美元，开盘价创八个多月新低
** 该公司称，一个独立委员会 (link)，建议停止其震颤药物试验，因为该试验不太可能达到研究的主要目标；PRAX称，将在改变分析方法后继续进行试验。
** 试验药物 ulixacaltamide 正在后期研究中进行测试，以治疗本质性震颤，本质性震颤是一种影响神经系统并导致不自主和有节奏颤抖的疾病。
** 股价在过去 12 个月中上涨了 33.1%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.